Telavancin for Hospital-Acquired Pneumonia: Clinical Response and 28-Day Survival

G. Ralph Corey, Marin H. Kollef, Andrew F. Shorr, Ethan Rubinstein, Martin E. Stryjewski, Alan Hopkins and Steven L. Barriere

AUTHOR CORRECTION

Telavancin for Hospital-Acquired Pneumonia: Clinical Response and 28-Day Survival

G. Ralph Corey, Marin H. Kollef, Andrew F. Shorr, Ethan Rubinstein, Martin E. Stryjewski, Alan Hopkins, Steven L. Barriere

Department of Medicine, Duke Clinical Research Institute, Durham, North Carolina, USA; Pulmonary and Critical Care Division, Washington University School of Medicine, St. Louis, Missouri, USA; Pulmonary and Critical Care Medicine, Washington Hospital Center, Washington, DC, USA; University of Manitoba, Winnipeg, Manitoba, Canada; Department of Medicine, Section of Infectious Diseases, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno, Buenos Aires, Argentina; Theravance, Inc., South San Francisco, California, USA

Volume 58, no. 4, p 2030–2037, 2014. Page 2030, right column, line 6. Since the suspension of the European marketing authorization for telavancin has now been lifted, the following text in the introduction no longer applies: “At the time of submission, the telavancin European marketing authorization for the treatment of nosocomial pneumonia was suspended pending evidence of a new European Medicines Agency-approved supplier. Clinigen Healthcare Ltd., Theravance’s commercialization partner for telavancin in Europe, is in the process of seeking approval of a new manufacturing source.”